1. Home
  2. MUX vs DMRA Comparison

MUX vs DMRA Comparison

Compare MUX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$20.42

Market Cap

1.6B

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$29.00

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MUX
DMRA
Founded
1979
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
MUX
DMRA
Price
$20.42
$29.00
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$26.63
$43.00
AVG Volume (30 Days)
1.1M
306.7K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
168.60
121.48
EPS
0.61
N/A
Revenue
$197,553,000.00
N/A
Revenue This Year
$37.86
N/A
Revenue Next Year
$31.10
N/A
P/E Ratio
$35.51
N/A
Revenue Growth
13.23
N/A
52 Week Low
$12.38
$16.50
52 Week High
$29.70
$34.89

Technical Indicators

Market Signals
Indicator
MUX
DMRA
Relative Strength Index (RSI) 57.07 46.05
Support Level $20.44 $28.16
Resistance Level $20.62 $34.23
Average True Range (ATR) 0.83 1.50
MACD 0.19 -0.25
Stochastic Oscillator 61.92 4.72

Price Performance

Historical Comparison
MUX
DMRA

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: